{
  "symbol": "ODTX",
  "company": "Odyssey Therapeutics, Inc.",
  "generated_at": "2026-06-24T07:36:30.058Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-05-12T01:13:17.853Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Pre-revenue clinical-stage biotech with no near-term catalysts (>12 months to data), negligible open-market insider buying ($120k), and explicit anti-signals for dilution and low liquidity. Fails asymmetric thresholds.",
      "trigger": "[insider_cluster_universe] 12 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-05-12T01:13:17.820Z",
      "skip": true,
      "reason": "Pre-revenue clinical-stage biotech with no near-term catalysts (>12 months to data), negligible open-market insider buying ($120k), and explicit anti-signals for dilution and low liquidity. Fails asymmetric thresholds.",
      "score": 8,
      "breakdown": {
        "smart_money": 3,
        "options_flow": 0,
        "catalyst": 5,
        "mispricing": 0,
        "quality": 0,
        "technical": 0
      },
      "debug_path": "drafts/2026-05-12-ODTX.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-12T01:12:36.493Z",
      "summary": "Odyssey Therapeutics IPO'd at $18/share on May 7-8, 2026. The stock has already traded below its IPO price ($16.42 on day 1), presenting a potential discount to the institutional base cost. A genuine insider cluster is present: Jeffrey Leiden (board chair, former Vertex CEO) bought 5,000 shares at $20 on May 8 open-market — above the IPO price; CFO Jason Haas also bought 1,000 shares at $20 same day; and Dimension Capital director Nan Li purchased 1,111,111 shares in the offering itself. The Phase 2a topline data for lead asset OD-001 (RIPK2 inhibitor) was delivered April 2026 showing patient benefit across multiple endpoints with no serious adverse events — yet the stock trades below IPO price. This creates a potential misalignment between near-term clinical inflection and public market pricing.",
      "verdict": "promising",
      "confidence": 4,
      "tool_calls": 14,
      "walltime_min": 6,
      "debug_path": "dossiers/2026-05-12-ODTX.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "call": "NO_DATA",
    "confidence": 0,
    "score": 0,
    "factors": {},
    "summary": "insufficient bars (31)",
    "ticker": "ODTX"
  }
}